Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Adaptive, Double-blinded, Placebo Controlled, Randomized, Multi-center Trial to Evaluate the Efficacy, Safety and Tolerability of Intracoronary Infusion of AB-1002 in Adult Subjects With New York Heart Association (NYHA) Class III Heart Failure and Non-ischemic Cardiomyopathy

Next Previous
Search
Trial Profile

A Phase 2, Adaptive, Double-blinded, Placebo Controlled, Randomized, Multi-center Trial to Evaluate the Efficacy, Safety and Tolerability of Intracoronary Infusion of AB-1002 in Adult Subjects With New York Heart Association (NYHA) Class III Heart Failure and Non-ischemic Cardiomyopathy

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AB 1002 (Primary)
  • Indications Cardiomyopathies; Heart failure
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GenePHIT
  • Sponsors Asklepios BioPharmaceutical

    • Most Recent Events

    • 13 Feb 2025 According to Bayer media release, the company announced that the first participant has been randomized in Europe in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase 2 clinical trial of AB-1002 for the treatment of congestive heart failure (CHF).
    • 28 Jun 2024 Planned End Date changed from 1 Dec 2030 to 31 Dec 2030.
    • 28 Jun 2024 Planned primary completion date changed from 1 Dec 2030 to 31 Oct 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top